Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG-641 in metastatic or advanced epithelial tumours
NCT04053283Phase 1Completed
- Sponsor
- Akamis Bio
- Start
- Jan 2020
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NG-641 in Epithelial tumor, sponsored by Akamis Bio. Primary endpoint: Incidence of adverse events. Started Jan 2020; status: completed.
02
Drugs
NG-641
03
Conditions
Epithelial tumor
Beyond the preview
Go deeper on NCT04053283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053283.